The Journal of Thoracic and Cardiovascular Surgery
Volume 131, Issue 3 , Pages 515-516 , March 2006

Anticoagulation for cardiopulmonary bypass: Is a replacement for heparin on the horizon?

  • Theodore E. Warkentin, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Theodore E. Warkentin, MD, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences (General Site), 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada

Received 1 November 2005 ,Accepted 1 November 2005.

References 

  1. Cohn LH . Fifty years of open-heart surgery . Circulation . 2003;107:2168–2170
  2. Ranucci M , Frigiola A , Menicanti L , Cazzaniga A , Soro G , Isgro G . Risk factors for fatal myocardial infarction after coronary bypass surgery . Eur J Anaesthesiol. . 2001;18:322–329
  3. Warkentin TE , Sheppard JI . No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure . J Thromb Haemost. . 2006;4:281–282
  4. Warkentin TE , Greinacher A . Heparin-induced thrombocytopenia and cardiac surgery . Ann Thorac Surg. . 2003;76:2121–2131
  5. Warkentin TE , Kelton JG . Delayed-onset heparin-induced thrombocytopenia and thrombosis . Ann Intern Med. . 2001;135:502–506
  6. Magnani HN , Beijering RJR , ten Cate JW , Chong BH . Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia . In:  Pifarré R editors. New anticoagulants for the cardiovascular patient . Philadelphia: Hanley & Belfus; 1997;p. 487–500
  7. Koster A , Hansen R , Kuppe H , Hetzer R , Crystal GJ , Mertzlufft F . Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II (a 1-year experience in 57 patients) . J Cardiothorac Vasc Anesth. . 2000;14:243–248
  8. Warkentin TE , Koster A . Bivalirudin (a review) . Expert Opin Pharmacother. . 2005;6:1349–1371
  9. Merry AF , Raudkivi PJ , Middleton NG , McDougall JM , Nand P , Mills BP , et al.   Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery . Ann Thorac Surg. . 2004;77:925–931
  10. Dyke CM , Smedira NG , Koster A , Aronson S , McCarthy HL , Kirshner R , et al.   A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass (The EVOLUTION-ON study) . J Thorac Cardiovasc Surg. . 2006;131:533–539

 Dr Warkentin has a financial relationship with several of the manufacturers (GlaxoSmithKline, Medicines Co., and Organon) of anticoagulants discussed in this editorial.

PII: S0022-5223(05)01915-X

doi: 10.1016/j.jtcvs.2005.11.012

The Journal of Thoracic and Cardiovascular Surgery
Volume 131, Issue 3 , Pages 515-516 , March 2006

Article Tools